S.M.A.R.T.® CONTROL® Iliac Stent System

First Nitinol Iliac Stent Indicated for Primary Stenting of Common and External Iliac Arteries

S.M.A.R.T.® CONTROL® Iliac Stent Results*

  • 95% primary patency, 12 months
  • 7% Adverse Event rate, 9 months+
  • 45% increase in MLD
  • 3.5% binary restenosis, 9 months
     

The S.M.A.R.T.® CONTROL® Iliac Stent System delivers notable patient results*

  • 30% improvement in ABI
  • 38% improvement in TBI
  • Patients Can Walk With Less Pain**
  • 58% Improvement in Walking Questionnaire Score
  • Observed Improvement in Walking Distance
     

Tantalum MicroMarker® Technology

  • 12 MicroMarkers define stent ends for easy visualization and placement
     

Flared Stent Ends

  • Immediate vessel wall apposition, for more accurate stent placement
  • Smooth access into vessel lumen
     

MicroMesh Geometry and Segmented Design

  • Superb radial strength for increased luminal diameter
  • Renowned vessel scaffolding and conformability to anatomy
     

Cordis TRUMARK® Technology

  • Precision stent placement and improved deliverability of catheter
     

Cordis S.M.A.R.T.® CONTROL® Stent Delivery Handle

  • One-handed or pin-and-pull (two-handed) delivery options
  • Enables incremental deployment and micro positioning of stent
     

Radiopaque Marker Band

  • Visualize stent deployment progress via opaque marker on outer catheter
     

 

For indications, contraindications, warnings, precautions, and adverse events, please read the Essential Prescribing Information (EPI).

Learn more about our full line of Endovascular products: Download the complete Endovascular product catalog PDF.

To place an order for a Cordis product please visit the
JOHNSON & JOHNSON GATEWAY® Commerce Web site at http://www.commerce.jnjgateway.com.

*From CRISP Trial Results, 12 month follow-up
**Based on Rutherford-Becker Scale classification pre-procedure versus 9-month follow-up
+Composite of binary restenosis, death at 30 days and TVR